A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the safety and immunogenicity of one dose of COMIRNATY in subjects that had received one dose of VAXZEVRIA (CombiVacS)
Purpose / Objectives
Primary Outcome
- To evaluate the relationship between the immune response measured as NAV
(Neutralizing antibodies) and antibodies against SARS-Cov2 spike protein measured by immunoassay.
Secondary Outcomes
- To assess the occurrence of symptomatic molecularly confirmed
COVID-19 and severity of COVID- 19 signs and symptoms after the
administration of a dose of COMIRNATY in subjects that received a prior single dose of VAXZEVRIA.
Study design
- Phase II
- Randomized
Documents (password protected)
Go to download area (no documents yet)